TransCode reports Phase 1a trial data for TTX-MC138 in solid tumors
Tweet Send to a Friend
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) released updated clinical data from its Phase 1a trial of TTX-MC138, an anti-miR-10b therapeutic candidate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




